Lexeo Therapeutics advanced regulatory discussions with the U.S. FDA regarding LX-2006, a gene therapy candidate for Friedreich ataxia cardiomyopathy. Interim clinical data show improvements in cardiac and neurological functions. The FDA indicated potential for accelerated approval based on pooled data from ongoing phase I/II studies, which could hasten the drug's path to market. This positions Lexeo at the forefront of treatment development for this progressive neurodegenerative condition with high unmet medical need.